Last reviewed · How we verify
NCT05102240
Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer
trial in Cervix Cancer in 1,800 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Tata Memorial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,800 |
| Start date | 24 February 2022 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across India |
Conditions studied
- Cervix Cancer — all drugs for Cervix Cancer →
Sponsor
Tata Memorial Hospital
Who can join
Adults 18 to 90, female only, with Cervix Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability Hypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05102240
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervix Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT07292818 — Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies · Phase 1 · recruiting
- NCT07435623 — Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study · recruiting
- NCT06904365 — Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women · recruiting
- NCT06416748 — Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer · NA · recruiting
Other Tata Memorial Hospital trials
Trials by the same sponsor.
- NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
- NCT07196033 — Asian Gynecological Brachytherapy Registry in Cervical Cancer · recruiting
- NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
- NCT07435623 — Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study · recruiting
- NCT07342231 — FAPi PET in Pancreatic Ductal Adenocarcinoma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05102240 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tata Memorial Hospital
- Last refreshed: 20 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05102240.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing